Tempus has entered a multi-year, pan-cancer research partnership with NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center. The program will enroll patients into a prospective observational trial, “Serial Molecular Profiling and Monitoring of Human Cancer,” sequencing tumors at multiple treatment milestones to generate longitudinal genomic data. Subsequent studies will validate novel assays, discover biomarkers, refine biological models, analyze real-world evidence and develop AI-driven predictive algorithms. The initiative leverages Tempus’s AI platform and one of the world’s largest multimodal data libraries, with the goal of accelerating the translation of molecular insights into individualized treatment strategies.

In collaboration with Northwestern Medicine, Tempus will roll out next-generation sequencing across nearly all cancer types, including early-stage diagnoses, within the Robert H. Lurie Comprehensive Cancer Center network. The agreement covers solid tissue, DNA/RNA profiling, liquid biopsy and minimal residual disease assays. Northwestern’s leadership expects the program to catalyze faster adoption of targeted therapies, accelerate enrollment in biomarker-driven clinical trials and broaden precision-oncology access across its patient population. Tempus CEO Eric Lefkofsky highlighted the partnership as a testament to the company’s operational scale and the breadth of its genomic portfolio.

Tempus reported select, unaudited preliminary results for the quarter and full year ended December 31, 2025. Full-year revenue reached approximately $1.27 billion, up 83% year-over-year, with organic growth of 30% after excluding Ambry. Diagnostics revenue totaled roughly $955 million, a 111% increase driven by 26% growth in oncology volumes and 29% in hereditary testing. Data and applications revenue amounted to about $316 million, up 31%, led by a 38% gain in data licensing. In Q4 alone, revenue was near $367 million, an 83% surge, with diagnostics up 121% and data licensing up 68% (excluding a prior-year warrant impact). Management cited record unit growth rates and strong AI-enabled product demand as key drivers heading into 2026.

As of December 31, 2025, Tempus achieved a record Total Contract Value exceeding $1.1 billion, marking its largest annual bookings to date. During the year, the company signed data and analytics agreements with more than 70 customers, including all top 10 global pharmaceutical firms—AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, AbbVie, Daiichi Sankyo, Eli Lilly and Boehringer Ingelheim—plus a broad roster of biotechnology partners. These contracts span multi-year commitments for access to Tempus’s de-identified genomic and clinical datasets, underpinning the company’s strategy to monetize its data assets and further entrench its AI-driven precision-medicine platform.